Acute lymphoblastic leukemia in patients treated with lenalidomide for multiple myeloma: a safety meta-analysis of randomized controlled trials combined with a retrospective study of the WHO's pharmacovigilance database

Blood Cancer J. 2024 Oct 14;14(1):177. doi: 10.1038/s41408-024-01154-z.
No abstract available

Publication types

  • Letter
  • Meta-Analysis
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Databases, Factual
  • Humans
  • Lenalidomide* / adverse effects
  • Lenalidomide* / therapeutic use
  • Multiple Myeloma* / drug therapy
  • Pharmacovigilance
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma* / chemically induced
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma* / epidemiology
  • Randomized Controlled Trials as Topic
  • Retrospective Studies
  • Thalidomide / adverse effects
  • Thalidomide / analogs & derivatives
  • Thalidomide / therapeutic use

Substances

  • Lenalidomide
  • Thalidomide